We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Chiesi to acquire 100% of Cornerstone Therapeutics

Chiesi to acquire 100% of Cornerstone Therapeutics

September 18, 2013
CenterWatch Staff

European pharma company Chiesi Farmaceutici will acquire 100% of Cornerstone Therapeutics, a North Carolina-based specialty pharmaceutical company commercializing products for the U.S. hospital and adjacent specialty markets.

Both companies’ boards of directors have approved the definitive merger agreement, under which Chiesi will acquire all outstanding common shares for $9.50 per share in cash. Chiesi currently owns 58% of the outstanding common shares.

The deal represents a 78% premium over Cornerstone’s closing price of $5.35 Feb. 15, 2013, the last trading day prior to Chiesi’s initial written proposal, and a 42% premium to the high end of the range of Chiesi’s initial proposal.

The buy advances Chiesi’s initiative to build a larger global presence and represents a significant step toward strengthening its presence in the U.S. The acquisition creates a foundation for new projects in special care and respiratory disorders and will provide a sales channel on all products Chiesi intends to commercialize in the U.S.

Through this transaction, Chiesi said it will become a bigger player in special care in the U.S., the world’s largest market for this type of care (50% of projects in orphan drugs originate in the U.S.). Chiesi’s product pipeline includes molecules for the treatment of respiratory and rare diseases, and will continue to develop its pipeline as it consolidates its presence in the U.S.

The transaction positions Cornerstone for long-term growth and development as a private company and affords a level of financial flexibility required to enhance its product pipeline, strengthen its marketing network and allow it to capitalize on additional opportunities to acquire high-quality respiratory products.

“We are excited to announce this transaction, which offers immediate and significant cash value to Cornerstone stockholders, and creates enhanced flexibility for Cornerstone to grow and prosper in the global marketplace,” said Ugo Di Francesco, CEO of Chiesi. “With the support of Chiesi, Cornerstone will help fulfill its mission to develop and commercialize innovative pharmaceutical solutions to improve the quality of human life.”

The transaction is expected to be completed in the first quarter of 2014, subject to conditions including the approval of a majority of Cornerstone’s stockholders.

A week earlier, Chiesi Group signed, through its U.K. affiliate, Chiesi Ltd., a definitive agreement with Sunstone Capital to acquire Zymenex Holding, a biopharmaceutical group focused on R&D of innovative biologic therapeutics to treat rare and life-threatening genetic diseases. Terms were not disclosed.

The acquisition includes Lamazym, a phase III recombinant enzyme to treat patients suffering from alpha-Mannosidosis, a genetic disease that causes a progressive impairment of the cental nervous system, as well as other early-stage compounds. The buy will establish an R&D position for Chiesi in the recombinant biologics market for rare diseases.

"This transaction marks Chiesi’s entrance into the rare disease space and provides an opportunity to access high-potential markets,” said Di Francesco. “Given the rarity of the condition and the importance of being close to the patients, we will consider setting up a standalone rare disease unit that would cover all major geographies, including the U.S.”

Chiesi expects to gradually integrate Zymenex into its R&D structure and retain the Zymenex and Lamazym brands.

Global News Drug Sponsors

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Patient-phsyician-consultation

    Giving Patients Back Their Voice in Clinical Trials

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing